Bayer’s Double-DARE Prostate Cancer Study Builds Real-World Case for Nubeqa

Bayer AG (BAYRY) announced an update on their ongoing clinical study.

The Double-DARE study from Bayer aims to track how U.S. urology clinics use darolutamide and similar drugs in men newly diagnosed with metastatic hormone-sensitive prostate cancer. It focuses on real-world patient traits, treatment patterns, and outcomes, which can guide doctors and inform how payers and investors view this fast-growing therapy area.

The study looks at several oral hormone drugs known as androgen receptor pathway inhibitors. These include Bayer’s darolutamide (Nubeqa) plus rivals abiraterone acetate, enzalutamide, and apalutamide, used either with standard hormone shots alone or in mix with chemotherapy to better control aggressive prostate cancer.

This is an observational, cohort-style study that uses past electronic health records rather than assigning treatments. There is no randomization or blinding, so the goal is not to prove cause and effect but to map how different drug combos are used in practice and what outcomes doctors are seeing across large community groups.

The study was first submitted on 14 Dec 2025, marking the formal launch of the data plan and protocol. The most recent update was filed on 31 Mar 2026, which signals active data work and keeps the recruiting status current for regulators, physicians, and investors tracking progress.

No primary or final completion dates are posted yet, so investors should expect a multi-year data build as more urology clinics contribute charts. The lack of reported results also means the current update is about study setup and execution, not yet about clinical performance or label-changing evidence.

For Bayer (BAYRY), this study could strengthen the commercial case for Nubeqa in a key early prostate cancer segment if real-world use looks broad and outcomes align with trials. Robust data may support better positioning versus Johnson & Johnson’s abiraterone and apalutamide and Pfizer/Astellas’ enzalutamide, and could feed into payer talks on access and pricing.

The update itself is not a near-term stock catalyst but does support the view that Bayer is investing to defend and grow its oncology franchise. Strong eventual findings could boost sentiment around long-term Nubeqa revenue, while weak or mixed patterns might narrow its edge in a very competitive ARPI field.

Overall, the Double-DARE study remains active and in the recruiting phase, with details and future updates available on the ClinicalTrials.gov portal under identifier NCT07406282.

To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.